Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)


Creative Commons License

Gibson C. M., Chi G., Halaby R., Korjian S., Daaboul Y., Jain P., ...Daha Fazla

CIRCULATION, cilt.135, sa.7, ss.648-655, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 135 Sayı: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1161/circulationaha.116.025427
  • Dergi Adı: CIRCULATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.648-655
  • Anahtar Kelimeler: anticoagulants, cardiology, cardiovascular diseases, intracranial hemorrhages, stroke, thrombosis, WARFARIN, OUTCOMES, CARE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

BACKGROUND: Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The potential of extended-duration thromboprophylaxis with the factor Xa inhibitor betrixaban to reduce the risk of stroke compared with standard-dose enoxaparin in this population was assessed in this retrospective APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).